National coverage of heart failure drug blocked by Medicare

Article Overview

This article covers a CMS national coverage decision involving a heart failure drug, the retroactive timing of the non-coverage action, and the context around FDA approval and carrier discretion. It is aimed at medical coders, billing staff, compliance teams, and other revenue cycle professionals who need to understand how payer policy changes can affect reimbursement and claim handling. The discussion stays focused on coverage status, regulatory context, and the organizations involved.